First Alzheimer's Drug to Slow Disease Is Approved by FDA

The approval of the Biogen drug, which has the molecular name aducanumab and will be sold as Aduhelm, marked a watershed in Alzheimer’s drug research after billions of dollars in investment.

Jump To The Original Source

Share this Story
Load More Related Articles
Load More In US News

Facebook Comments

Check Also

Nets’ season comes to an end after overtime loss to Bucks in Game 7

Published by New York Daily News NEW YORK ...

Archives